Prelude Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Prelude Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200	Closed	-$4K	–	2618
2020 Q2	$4K	Buy	+200	New	+$2.78K	﹤0.01%	1770

Prelude Capital Management's PTLA Position: Q3 2020 in Review

Prelude Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 259,762 shares — an estimated $4.67M sold.

Prelude Capital Management first reported a position in PTLA in Q4 2014 and held it in 10 quarters. The position peaked at $4.67M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Prelude Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Prelude Capital Management sold 259,762 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $4.67M.
Prelude Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 10 quarters.
Prelude Capital Management's Portola Pharmaceuticals, Inc. position peaked at $4.67M in Q2 2020.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.